Clinical trials: Chronic Obstructive Pulmonary
Pulmonary Disease, Chronic Obstructive
Postmarketing Surveillance Study to Assess Handling and Patient Satisfaction on Berodual® Respimat® Solution for Inhalation in Patients With Chronic Obstructive Pulmonary Disease
New perceptions about handling and patient satisfaction of the everyday use of Berodual® Respimat® in patients with chronic obstructive lung disease (COLD).
- Trial name
- NCT02231320
- Testing
- Berodual® Respimat® - inhaler
- Volunteers
- 236 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive
Safety, Tolerability and Pharmacokinetics (PK) Study of GSK2269557 in Healthy Subjects
GSK2269557 is being developed as an anti-inflammatory and anti-infective agent for the treatment of inflammatory airways diseases.
- Trial name
- NCT03189589
- Testing
- GSK2269557 500 µg, GSK2269557 750 µg
- Where
- United Kingdom
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
COPD
Pharmacodynamics, Pharmacokinetics and Safety of Two Doses of CHF6001 DPI in Subjects With Moderate, Severe COPD
Effect of CHF 6001 on biomarkers of inflammation in induced sputum and in blood, on pulmonary function and on symptoms benefits in comparison with placebo.
- Trial name
- NCT03004417
- Testing
- CHF 6001 Dose1, CHF 6001 Dose2
- Where
- United Kingdom
- Volunteers
- 61 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
COPD
Assessing Exercise Capacity After PulseHaler™ Treatment in GOLD II-IV COPD Patients
Prospective, sham controlled, interventional study to evaluate the extent to which PulseHaler improves the functional status of Chronic Obstructive Lung Disease (GOLD) II-IV Chronic obstructive pulmonary disease (COPD) patients.
- Trial name
- NCT04236076
- Testing
- PulseHaler
- Volunteers
- 104 people
- Sponsor
- Respinova LTD
Respiratory Failure, Neuromuscular Disease
Ventilator Monitoring in Early Exacerbation Detection
The aim of this study is to determine whether respiratory disease exacerbations (a sudden worsening of symptoms) can be predicted by variables that are monitored by non-invasive ventilators (small machines that assist breathing)…
- Conditions
- Respiratory Failure, Neuromuscular Disease, Chest Wall Disorder, Chronic Obstructive Pulmonary Disease
- Trial name
- NCT01644162
- Testing
- iVAPS ventilation
- Where
- United Kingdom
- Volunteers
- 30 people
- Sponsor
- ResMed
Pulmonary Disease, Chronic Obstructive (COPD)
Real-world, 52-week Prospective Study to Capture the Reasons for Switch to Triple Combination Therapy, Assess the Clinical and Patient Reported Outcomes in Adults With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) Treated With Trixeo Aerosphere™ in Routine Care Settings in Greece
Chronic obstructive pulmonary disease (COPD) is a debilitating and progressive respiratory condition characterized by irreversible airflow limitation.
- Trial name
- TRIAENA (NCT05915182)
- Testing
- Budesonide Glycopyrronium bromide Formoterol fumarate pressurized Metered Dose Inhaler
- Where
- 15 sites in Greece
- Volunteers
- 212 people
- Sponsor
- AstraZeneca
Pulmonary Disease, Chronic Obstructive
Effects of Once Daily Tiotropium in Patients With Chronic Obstructive Pulmonary Disease (COPD) of Different Severity
The primary objective of this study is to investigate the effect of tiotropium vs. placebo on trough FEV1 and FEV1 2 hours post inhalation after 12 weeks of treatment. For both endpoints changes from baseline will be analysed.
- Trial name
- NCT00274573
- Testing
- Tiotropium bromide
- Where
- 177 sites in Germany
- Volunteers
- 1,639 people
- Sponsor
- Boehringer Ingelheim
Kidney Diseases, Chronic Renal Insufficiency
Study to Compare Sevelamer Carbonate Powder to Sevelamer Hydrochloride Tablets in Patients With CKD on Hemodialysis
Approximately 207 patients with chronic kidney disease (CKD) on hemodialysis will be entered into this study at approximately 26 centers in the United States.
- Conditions
- Kidney Diseases, Chronic Renal Insufficiency, End-Stage Renal Disease
- Trial name
- NCT00268957
- Testing
- Sevelamer carbonate (Renvela®), Sevelamer hydrochloride (Renagel®)
- Where
- 29 sites in United States
- Volunteers
- 217 people
- Sponsor
- Genzyme, a Sanofi Company
Chronic Obstructive Pulmonary Disease
Evaluation of Efficacy and Safety of Formoterol in Patients With COPD Compared With Placebo in Patients in Japan, EU
The purpose of this study is to show the efficacy and safety of formoterol for the maintenance treatment of patients with COPD compared with placebo in patients in Japan and in European countries during 12 weeks.
- Trial name
- OCEAN (NCT00628862)
- Testing
- Formoterol Turbuhaler® 4.5mg, Formoterol Turbuhaler® 9 mg
- Where
- 47 sites in Bulgaria, Japan and 3 more
- Volunteers
- 613 people
- Sponsor
- AstraZeneca
Pulmonary Disease, Chronic Obstructive
Greek NIS Spiolto ELLACTO
Open-label observational study: including COPD patients receiving treatment with Spiolto® Respimat® for approximately 6 weeks, which is the average time between two medical consultations
- Trial name
- NCT03419962
- Testing
- MaxSpiolto® Respimat® 160 Characters...
- Where
- 15 sites in Greece
- Volunteers
- 1,360 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive
ICS/LABA Adherence and COPD Exacerbation
The purpose of this retrospective, non-interventional sutdy is to compare the effectiveness of ICS/LABA combination therapy in the reduction of COPD exacerbations during the 12 months after initiation of therapy between COPD…
- Trial name
- NCT02446041
- Testing
- Non-Interventional Study
- Where
- United States
- Volunteers
- 10,000 people
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease
A Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of Ensifentrine in Patients With COPD
The purpose of this study is to evaluate the efficacy and safety of ensifentrine in patients with moderate to severe Chronic Obstructive Pulmonary Disease (COPD).
- Trial name
- NCT04535986
- Testing
- Ensifentrine
- Where
- 122 sites in United States, Bulgaria and 10 more
- Volunteers
- 763 people
- Sponsor
- Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA
COPD, Hypercapnic Respiratory Failure
The Effects of Airtrapping on Sleep and Breathing in Non Invasive Ventilation (NIV) in COPD
15 COPD patients will be surveyed in this prospective randomized crossover pilot study concerning non invasive ventilation. Patients will be treated over 2 nights in randomized order with Ventimotion2 (Weinmann) with and without…
- Trial name
- NCT01987661
- Testing
- BIPAP ST, Airtrap
- Where
- Germany
- Volunteers
- 10 people
- Sponsor
- Institut für Pneumologie Hagen Ambrock eV
COPD
Portable Positive Pressure Therapy Device
This study will assess the impact the BREATHE device provides on post-exertion recovery time in COPD patients when used during and/or after performing an Activity of Daily Living simulation.
- Trial name
- NCT04452851
- Testing
- BREATHE, BiPAP, COPD Inhaler
- Volunteers
- 20 people
- Sponsor
- Koronis Biomedical Technologies
Pulmonary Disease, Chronic Obstructive
A 3 Way Cross-over Study Evaluating the Effects of ADOAIR Twice Daily Plus Tiotropium Bromide Once Daily Compared With the Individual Treatments of Japanese Subjects
The purpose of this study is to evaluate the effects on lung function of a combination of ADOAIR 50/250mcg twice daily plus tiotropium bromide 18mcg once daily compared with the individual treatments (tiotropium bromide 18mcg…
- Trial name
- SCO116572 (NCT01751113)
- Testing
- fluticasone propionate/salmeterol, tiotropium bromide, fluticasone propionate/salmeterol plus tiotropium bromide
- Where
- 3 sites in Japan
- Volunteers
- 53 people
- Sponsor
- GlaxoSmithKline
COPD
Safety, Tolerability and Pharmacodynamics of QAX028 Compared to Open-label Tiotropium Bromide and Placebo in Mild-to-moderate Chronic Obstructive Pulmonary Disease (COPD) Patients.
This will be a single dose Proof-of-Concept study in mild-to-moderate COPD patients. The study will investigate the safety and tolerability of QAX028 as well as the bronchodilatory effects of QAX028 compared to tiotropium and…
- Trial name
- NCT00568503
- Testing
- QAX028, Tiotropium bromide
- Where
- Denmark
- Volunteers
- 29 people
- Sponsor
- Novartis
Low Back Pain
Efficacy and Safety of Lymphdiaral Basistropfen (HDC) in the Treatment of Chronic Low-back Pain
To evaluate superiority of HDC in comparison to placebo in the treatment of chronic low-back pain in relation to pain, functional impairment, quality of life, and state of health during a 15-week treatment period.
- Trial name
- 144 (NCT01049373)
- Testing
- HDC
- Where
- Germany
- Volunteers
- 221 people
- Sponsor
- Pascoe Pharmazeutische Praeparate GmbH
Rhinosinusitis Acute, Rhinosinusitis Chronic
Sinolpan® Pharmacy Non-interventional Study - Quality of Live
This non-interventional study investigates the Quality of Life of patients suffering from rhinosinusitis. Patients who seek advice in a pharmacy and choose to intake Sinolpan® or Sinolpan® forte or to use nasally applied…
- Conditions
- Rhinosinusitis Acute, Rhinosinusitis Chronic, Bronchitis
- Trial name
- NCT04703673
- Testing
- Cineole, Nasal Decongestant
- Where
- Germany
- Volunteers
- 350 people
- Sponsor
- Engelhard Arzneimittel GmbH & Co.KG
Sleep Apnea, Obstructive, Chronic Obstructive Pulmonary Disease
SNORE (Smartphone Analyses of Nocturnal Obstruction by Respiratory Evaluation) SOUNDS
This is a prospective multipart clinical performance study to compare the ability of the SnoreSounds algorithm with polysomnography (PSG) and a type III Home Sleep Testing (HST) device to identify patients with obstructive sleep…
- Trial name
- SNORESOUNDS (NCT03288376)
- Where
- 3 sites in United States
- Volunteers
- 272 people, healthy volunteers welcome
- Sponsor
- Incyphae, Inc.
Chronic Obstructive Pulmonary Disease
PT005 MDI Dose Ranging Versus Foradil Aerolizer Study
The purpose of this study is to evaluate the safety and efficacy of inhaled PT005 MDI compared to placebo and Foradil Aerolizer in patients with moderate to severe chronic obstructive pulmonary disease (COPD).
- Trial name
- NCT01349868
- Testing
- PT005 MDI, Formoterol Fumarate 12 μg (Foradil® Aerolizer®), Formoterol Fumarate 24 μg (Foradil® Aerolizer®)
- Where
- 3 sites in United States
- Volunteers
- 50 people
- Sponsor
- Pearl Therapeutics, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.